Finding a new treatment target for Babesia infections.
Identifying the Target of a Potent and Selective Inhibitor of Babesia Blood Stages.
['FUNDING_R21'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-10661759
This study is looking at a new treatment called C10 that could help people with weakened immune systems who are infected with Babesia, a tick-borne disease, by figuring out how it works against the parasites causing the infection.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10661759 on ClinicalTrials.gov |
What this research studies
This research focuses on identifying the specific target of a new small molecule inhibitor, C10, which shows promise in treating Babesia infections, particularly in individuals with weakened immune systems. The study employs advanced genetic and biochemical techniques to pinpoint the proteins in the Babesia parasites that interact with the inhibitor. By understanding how C10 works, researchers aim to develop more effective treatments for this rising tick-borne disease, which has limited current treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are immunocompromised or asplenic and at risk for severe Babesia infections.
Not a fit: Patients who are not infected with Babesia or those with robust immune systems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective and safer treatment for patients suffering from Babesia infections.
How similar studies have performed: Other research has shown promise in developing targeted therapies for parasitic infections, suggesting that this approach could yield significant advancements.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAFSACK, BJORN FELIX CAESAR — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: KAFSACK, BJORN FELIX CAESAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Babesia infection, Babesia parasite infection